Reckamp, Karen
Lin, Huamao M.
Huang, Joice
Proskorovsky, Irina
Reichmann, William
Krotneva, Stanimira
Kerstein, David
Huang, Hui
Lee, Joseph
Clinical trials referenced in this document:
Documents that mention this clinical trial
Comparative efficacy of brigatinib versus ceritinib and alectinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancer
https://doi.org/10.1080/03007995.2018.1520696
Documents that mention this clinical trial
Neuroendocrine phenotype as an acquired resistance mechanism in ALK-rearranged lung adenocarcinoma
https://doi.org/10.1016/j.lungcan.2015.12.001
Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis
https://doi.org/10.1016/j.lungcan.2015.09.009
Comparative efficacy of brigatinib versus ceritinib and alectinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancer
https://doi.org/10.1080/03007995.2018.1520696
Documents that mention this clinical trial
Treatment and detection of ALK-rearranged NSCLC
https://doi.org/10.1016/j.lungcan.2013.03.017
Comparative efficacy of brigatinib versus ceritinib and alectinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancer
https://doi.org/10.1080/03007995.2018.1520696
Documents that mention this clinical trial
Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer
https://doi.org/10.1136/esmoopen-2018-000364
ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression
https://doi.org/10.1016/j.lungcan.2015.09.006
Comparative efficacy of brigatinib versus ceritinib and alectinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancer
https://doi.org/10.1080/03007995.2018.1520696
Documents that mention this clinical trial
Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis
https://doi.org/10.1016/j.lungcan.2015.09.009
Comparative efficacy of brigatinib versus ceritinib and alectinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancer
https://doi.org/10.1080/03007995.2018.1520696
Peer Review Statement: The publishing and review policy for this title is described in its Aims & Scope.
Publication History
Received: 2018-05-24
Revised: 2018-08-29
Accepted: 2018-09-04
Published: 2018-10-05